An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
Latest Information Update: 03 Aug 2022
At a glance
- Drugs TAK 748 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Baxalta
Most Recent Events
- 29 Jun 2021 Status changed from suspended to discontinued.
- 01 Jun 2021 This trial has been discontinued in Austria, as per European Clinical Trials Database record
- 16 May 2021 This trial has been discontinued in Hungary, as per European Clinical Trials Database record.